Open Access Open Access  Restricted Access Access granted  Restricted Access Subscription or Fee Access

No 16 (2014)

Articles

pages 11-12 views

Statiny i risk vozniknoveniya novykh sluchaev sakharnogo diabeta: sootnoshenie riska i pol'zy. Sovremennye predstavleniya o tselevykh urovnyakh lipidov u patsientov s sakharnym diabetom

Shalaev S.V., Safiullina Z.M., Mikhal'chuk N.A.

Abstract

In recent years, data on the increase of risk of new diabetes cases in patients receiving statins appear in the literature. This review examines recent studies devoted to this problem, the possible mechanisms of impaired glucose metabolism against the background of statin therapy. Target levels of atherogenic lipids in patients with diabetes, presented in the current national and European guidelines, are analyzed.
Pharmateca. 2014;(16):14-18
pages 14-18 views

Fiksirovannaya kombinatsiya saksagliptina i metformina modifitsirovannogo vysvobozhdeniya - novyy shag v uluchshenii priverzhennosti k lecheniyu sakharnogo diabeta 2 tipa

Biryukova E.V.

Abstract

Currently, growing evidence-based data in the field of diabetology indicate that the optimal components for the realization of the concept of modern fixed combination (FC) includes saxagliptin and metformin MR. New FC of saxagliptin and metformin MR, Kombiglyce Prolong, has a high efficiency, good safety and tolerability profile, and convenient to use. These benefits all allow to improve patients’ adherence to the treatment of type 2 diabetes mellitus.
Pharmateca. 2014;(16):19-25
pages 19-25 views

Optimizatsiya lecheniya patsientov s akromegaliey: uvelichenie intervala mezhdu in\"ektsiyami pri ispol'zovanii lanreotida

Antsiferov M.B., Pronin V.S.

Abstract

The article discusses various schemes of transfer of patients receiving octreotide, on lanreotide on (Somatulin® Autogel®) in order to optimize therapy by increasing the interval between injections. The results of the last large study in this area, and own author’s data are presented. Increase of the interval between injections of lanreotide while maintaining the therapeutic effect allows to significantly simplify the regimen of injections and improve patients' adherence to therapy.
Pharmateca. 2014;(16):26-29
pages 26-29 views

Novye podkhody k terapii bolezni Itsenko-Kushinga

Antsiferov M.B.

Abstract

Treatment of Cushing’s disease (CD) is a clinical challenge, an effective solution of which depends on the accuracy of the diagnosis, a correct assessment of the severity of hypercortisolism and the severity of the disease, as well as an individual approach to the choice of treatments. Introduction of pasireotide (Signifor) into clinical practice allows to achieve clinical and laboratory remission of CD and reduce the size of the tumor. Thus, pasireotide is an effective drug for the specific treatment of corticotroph adenomas in patients with CD.
Pharmateca. 2014;(16):30-36
pages 30-36 views

Kompleksnoe lechenie erektil'noy disfunktsii u muzhchin s ozhireniem

Ametov A.S., Stel'makh M.V.

Abstract

Obesity is one of the most important public health problems due to their common association with many chronic diseases including metabolic syndrome, type 2 diabetes, cardiovascular disease, dyslipidemia. Moreover, obesity is associated with a high prevalence of erectile dysfunction (ED); however, the pathophysiological link between these states are still poorly understood. A major role in the treatment of erectile dysfunction in obese men, along with drugs aimed at the normalization of erection should take therapy that promotes weight loss. Treatment of ED and obesity should be carried out simultaneously, as the simultaneous existence of these two pathologies support depression, which significantly worsens the prognosis of treatment. Therefore, in men with erectile dysfunction, obesity and requires the use of combined treatment aimed at reducing body weight, and sexual dysfunction. In this study, the findings suggest that the positive effect of weight loss, and as a result reduce the impact of the phenomenon of lipotoxicity on androgen status in men with obesity. It was shown that the weight loss program is not sufficiently effective, and that in men with ED, obesity and drug treatment should be carried out.
Pharmateca. 2014;(16):37-42
pages 37-42 views

Analiz effektivnosti i bezopasnosti primeneniya otechestvennogo insulina Rinsulin NPKh v gorode Nizhniy Novgorod

Zanozina O.V., Sorokina Y.A., Lovtsova L.V., Borovkov N.N.

Abstract

The article presents the results of the study aimed to the evaluation of the efficacy and safety of insulin isophane Rinsulin NPH (n = 23) and Humulin NPH (n = 14) in 37 patients with diabetes mellitus (DM) type 2, in which previous therapy with oral hypoglycemic agents in the maximum doses was ineffective. The data obtained suggest that there were no significant differences in the effects of Rinsulin NPH and Humulin NPH in patients with DM 2 during insulin therapy for 8 weeks. These drugs can be used for initiating insulin therapy in patients previously not treated with insulin, and also for replacement of other insulin preparations, if necessary. In case of transfer from other brands of insulin to Rinsulin NPH, the use of same doses and regimens with subsequent correction of the results by self-control can be recommended, as in other cases of replacement of insulin preparations.
Pharmateca. 2014;(16):43-47
pages 43-47 views

Kombinirovannaya terapiya bolevoy diabeticheskoy polineyropatii: rezul'taty pilotnogo issledovaniya

Khramilin V.N., Andreeva V.L., Demidova I.Y.

Abstract

Neuropathic pain as a manifestation of diabetic polyneuropathy (DPN) is a leading cause of seeking medical care for patients with diabetes mellitus. Limited efficacy of existing therapies is the main problem in the management of these patients. The main objective of the study was to assess the efficacy and safety of symptomatic, pathogenetic and combination therapy in patients with chronic painful DPN with moderate and severe sensory deficit, who were nonresponders to intravenous treatment with α-lipoic acid (ALA). Additional aim was to evaluate the efficacy and safety of combination therapy with gabapentin and gabapentin + vitamin B complex (Kombilipen® Tabs) in patients resistant to monotherapy with gabapentine. Prolonged use of ALA, as well as additional treatment with B vitamins in patients with moderate to severe painful DPN, which are nonresponders to intravenous therapy with ALA, had a small effect. In this situation, the appointment of symptomatic drugs with central action (gabapentin) as both monotherapy and in combination with ALA is reasonable. Application of a complex of B vitamins (Kombilipen® tabs) in patients-nonresponders to gabapentin is accompanied by an additional significant reduction in the severity of neuropathic pain.
Pharmateca. 2014;(16):48-53
pages 48-53 views

Leptin i gormonal'no-metabolicheskie pokazateli u bol'nykh bronkhial'noy astmoy i pri ee sochetanii s sakharnym diabetom 2 tipa

Verbovoy A.F., Sharonova L.A., Akhmerova R.I.

Abstract

The article presents the results of assessment of concentration of adipokines, and hormonal and metabolic parameters in women with bronchial asthma and its combination with type 2 diabetes mellitus. Hyperleptinemia, hyperresistinemia, and the tendency to the increase of adiponectin levels on the background of subclinical inflammation were revealed in all groups of patients. All of the women surveyed had pronounced insulin resistance accompanied by compensatory hyperinsulinemia, and atherogenic dyslipidemia.
Pharmateca. 2014;(16):54-57
pages 54-57 views

Vliyanie kratkosrochnoy terapii rozuvastatinom na pokazateli lipidnogo obmena u bol'nykh ishemicheskoy bolezn'yu serdtsa

Chavdar F.N., Kovaleva Y.V., Maslov A.P., Baranova M.N., Ryzhkova N.V., Bazhenova L.N., Getman Z.V.

Abstract

The evaluation of the influence of therapy with Mertenil (rosuvastatin), produced by the «Gedeon Richter» company, on lipid profile and blood biochemical parameters in 50 patients with coronary artery disease in a traditional medical practice was performed. It was shown that the use of rosuvastatin at initial dose of 10 mg/day for a month has allowed to achieve the target low density lipoprotein (LDL) cholesterol levels in 42% of patients. As a result of this treatment, the LDL cholesterol and triglycerides levels have decreased by 27 and 37%, respectively, and the high-density lipoprotein cholesterol levels have increased by 9%. Mertenil (rosuvastatin) was well tolerated and did not cause side effects.
Pharmateca. 2014;(16):58-61
pages 58-61 views

Issledovanie ORIGIN (Outcome Reduction with Initial Glargine INtervention) 2 goda spustya: chto novogo?

Glinkina I.V.

Abstract

The article considers outcomes of the ORIGIN study, the main results of which were first presented in 2012. The main purpose of this study was to evaluate the effects of therapy with insulin glargine (IG) compared with standard glucose-lowering therapy (in combination with ω-3 polyunsaturated fatty acids or placebo) in relation to the reducing the risk of cardiovascular diseases (CVD) and / or mortality in patients with prediabetes or «early» type 2 diabetes mellitus (DM) and high cardiovascular risk. Subsequently, ORIGIN study was expanded through several additional studies and a subanalyses, the results of which are discussed in this review. It has been shown that treatment with IG provides a stable, long-term glycemic control, with neutral impact on the cardiovascular outcomes, relatively low risk of hypoglycemia and small weight gain. Achievement of the fasting normoglycemia as a result of therapy with IG allows to reduce the risk of microvascular complications. Compared with standard therapy, severe hypoglycemia during therapy with the IG is less associated with the cardiovascular outcomes. Therapy with IG slows the progression of atherosclerosis, but has no effect on the progression of cognitive dysfunction. The presence of long-term effects of the therapy applied in the ORIGIN study will be known after the analysis of the results of ORIGINALE study (follow-up over participants of the ORIGIN study).
Pharmateca. 2014;(16):62-71
pages 62-71 views

Effektivnost' i bezopasnost' primeneniya dvukhfaznogo analoga insulina NovoMiks 30 pri sakharnom diabete 2 tipa: ot klinicheskikh issledovaniy do real'noy praktiki

Surkova E.V.

Abstract

Biphasic (or premix) formulations of insulin contain a fixed ratio of short- (or ultra-short-) and intermediate-action insulin. Currently, this group includes several products of premixed insulin both human insulin as well as insulin analogues. NovoMix 30 is used in the world clinical practice for over 10 years and remains one of the most studied preparation of insulin; efficacy and safety of NovoMix 30 are confirmed by numerous randomized clinical trials and large observational programs. Comparative studies of NovoMix 30 and biphasic human insulins, as well as analogues insulins with different ratios of short-acting and long-acting fractions were performed. The studies' results demonstrated a high level of efficiency and safety, especially with regard to the risk of hypoglycemia and the effect on body weight. NovoMix 30 is suitable for both initiation and for the intensification of insulin therapy, because enables the use of one drug in a single insulin delivery system, with individual adjusting doses and increase the number of injections, if needed. Furthermore, the use of a simple titration algorithm enhances adherence of patients to a regimen of therapy recommended by a physician.
Pharmateca. 2014;(16):72-79
pages 72-79 views

Primenenie kombinirovannoy terapii glimepiridom i metforminom u patsientov s sakharnym diabetom 2 tipa. Rezul'taty Rossiyskogo observatsionnogo issledovaniya

Zaytseva N.V., Shamkhalova M.S.

Abstract

Lifestyle modification, which is the first step in the treatment of type 2 diabetes mellitus, even in case of simultaneous beginning of therapy with metformin, often does not lead to the achievement of carbohydrate metabolism control. Glimepiride, a representative of the third generation sulfonylureas, is one of the drugs of choice for the enhancement of antihyperglicemic therapy. The article presents the results of open multicenter observational study on the efficacy and safety of combined use of metformin and glimepiride, allows to significantly improve the status of carbohydrate metabolism in patients with type 2 diabetes mellitus. This therapy is safe due to the low risk of hypoglycaemia, lack of side effects and adverse effects on body weight.
Pharmateca. 2014;(16):80-85
pages 80-85 views

Preparat Vazomirin v terapii tsentral'nogo nesakharnogo diabeta u detey

Mazerkina N.A.

Abstract

The article considers the etiopathogenesis and principles of diagnosis of central diabetes insipidus (CDI); the features of disease in neurosurgical practice are discussed. In particular, the practicability of the use of intranasal dosage form of desmopressin (Vazomirin) in the treatment of such patients is justified. Clinical example of the successful use of this drug by patient 4.5 years old with CDI after removal of intraextraventricular craniopharyngioma is presented. It is emphasized that the Vazomirin is effective drug in the therapy of CDI in neurosurgical practice, does not cause significant side effects and can be used in pediatric practice.
Pharmateca. 2014;(16):86-90
pages 86-90 views

Aktual'nye voprosy kontrolya arterial'noy gipertenzii i narusheniya lipidnogo obmena: fokus na priverzhennost'

Nebieridze D.V., Sarycheva A.F., Kamyshova T.V.

Abstract

The article presents the results of the study aimed to the assessment of effectiveness of therapy with a fixed combination of amlodipine and atorvastatin (Duplecor) in patients with arterial hypertension (AH) and associated dyslipidemia (DLE). It has been shown that the use of a fixed combination Duplecor is convenient, safe and effective approach to the simultaneous control of two major cardiovascular risk factors. Easy to administrate formulation - one tablet instead of two tablets - can greatly simplify the treatment of AH and DLE, and therefore improve patient’s adherence to drug therapy.
Pharmateca. 2014;(16):91-95
pages 91-95 views

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies